Subscribe now to be first to hear about some of Australia's best investment opportunities.
Subscribe NowArtrya Limited (ASX:AYA) is a Perth-based medical technology, software-as-a-service company at the forefront of AI-driven diagnostic imaging tools for coronary artery disease. Artrya has developed Salix, an AI-driven coronary diagnostic and workflow platform that assesses high-risk plaques and coronary blood flow and significantly improves the speed and accuracy of CCTA imaging reporting at the point of care and in near real-time.
Recommendation: We rate Artrya as a buy, and believe the stock is well undervalued. Artrya is transitioning from pre-revenue and over the next 12 months will achieve several milestones that will see it re-rate. See out latest report for the most up to date information. For a complete overview of the company, please download our initiation of coverage report.
*General advice only. See full disclosures and disclaimers.
Venn Brown © 2025